Zosano Pharma Corp. announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application titled Method of Rapidly Achieving Therapeutic Concentrations of Triptans for Treatment of Migraines. In February 2017, Zosano reported positive pivotal data from their Zotrip Phase 2/3 trial, in which subjects treated with the 3.8mg dose of M207 achieved statistical significance on the co-primary endpoints. This newly-allowed patent application contains claims generated from formulation, preclinical and clinical studies, and highlights the unique aspects of the Zosano technologies and their applicability for treatment of migraine. This allowance expands the breadth of and further validates their intellectual property portfolio for their ADAM technology, and specifically M207. It covers method of use, formulation, delivery system, pharmacokinetic profile and the pharmacodynamic response. Zosano’s patent estate additionally includes other granted U.S. and foreign patents and pending patent applications covering their ADAM technology, including their microneedle technology, drug formulations, methods of use and applicators.